Vanta Bioscience Ltd
Vanta Bioscience Ltd (VANTABIO) last reported results for the quarter ended Mar 2026, with sales of ₹1.51 crore and net profit of ₹1.93 crore. The stock last traded at ₹20.4, a market capitalisation of ₹14.5 crore, on a P/E of 132. Over the past 52 weeks the stock has ranged between ₹14.7 and ₹29. Figures are as of 6 Oct 2026 and are not real time.
Vanta Bioscience Ltd share price and key metrics
- Current price
- ₹20.4
- Market cap
- ₹14.5 cr
- Stock P/E
- 132
- Book value
- ₹29.8
- ROE
- 0.70%
- ROCE
- 1.19%
- Dividend yield
- 0.00%
- 52w high / low
- 29.0/14.7
Metrics as of 6 Oct 2026. Not real time.
Track Vanta Bioscience Ltd
Cruxal reads every Vanta Bioscience Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Vanta Bioscience Ltd growth and returns
- 10 Years
- %
- 5 Years
- -29%
- 3 Years
- -32%
- TTM
- -7%
- 10 Years
- %
- 5 Years
- -24%
- 3 Years
- 26%
- TTM
- 102%
- 10 Years
- %
- 5 Years
- -32%
- 3 Years
- -23%
- 1 Year
- -16%
- 10 Years
- %
- 5 Years
- -15%
- 3 Years
- -16%
- Last Year
- 1%
Vanta Bioscience Ltd quarterly results
In the quarter ended Mar 2026, sales were ₹1.51 cr, up 357.6% from ₹0.33 cr a year earlier. Net profit turned positive at ₹1.93 cr.
| ₹ crore | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2.82 | 3.45 | 6.18 | 3.55 | 1.03 | 0.33 | 0.3 | 1.51 |
| Expenses | 3.37 | 5.3 | 4.12 | 4.3 | 1.42 | 2.01 | 0.67 | 0.13 |
| Operating profit | -0.55 | -1.85 | 2.06 | -0.75 | -0.39 | -1.68 | -0.37 | 1.38 |
| OPM % | -19.50% | -53.62% | 33.33% | -21.13% | -37.86% | -509.09% | -123.33% | 91.39% |
| Other income | 0.01 | 0.68 | 0.03 | 0.08 | 0.04 | 0.04 | -0 | 0.16 |
| Interest | 2.48 | 3.4 | 2.85 | 2.9 | 2.14 | -0.06 | 0.88 | -0.11 |
| Depreciation | 1.31 | 1.36 | 1.54 | 2.95 | 1.69 | -0.17 | 0.61 | -0.23 |
| Profit before tax | -4.33 | -5.93 | -2.3 | -6.52 | -4.18 | -1.41 | -1.86 | 1.88 |
| Tax % | 2.08% | 1.52% | -0.87% | -3.07% | -1.20% | -2.13% | -2.69% | -2.66% |
| Net profit | -2.56 | -3.92 | -0.54 | -1.78 | -2.07 | -1.37 | -1.82 | 1.93 |
| EPS (₹) | -4.06 | -6.21 | -0.86 | -2.82 | -3.28 | -2.17 | -2.56 | 2.71 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Vanta Bioscience Ltd annual results
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 12.08 | 13.75 | 9.82 | 9.4 | 5.83 | 9.72 | 1.96 | 1.82 |
| Operating profit | 3.27 | 4.37 | 3.95 | 3.47 | -2.39 | 1.31 | -4.25 | 1.02 |
| OPM % | 27.07% | 31.78% | 40.22% | 36.91% | -40.99% | 13.48% | -216.84% | 56.04% |
| Net profit | 0.7 | 1.01 | 0.45 | 0.14 | -10.44 | -8.61 | -13.29 | 0.11 |
| EPS (₹) | 1.11 | 1.58 | 0.71 | 0.14 | -10.27 | -3.68 | -7.56 | 0.15 |
TTM is the trailing twelve months to the most recent quarter.
Vanta Bioscience Ltd balance sheet
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 7.11 |
| Reserves | 15.94 | 17.16 | 17.61 | 17.70 | 11.20 | 8.89 | 4.11 | 14.06 |
| Borrowings | 13.25 | 17.37 | 35.97 | 44.86 | 57.16 | 60.96 | 70.09 | 38.08 |
| Other liabilities | 3.51 | 7.74 | 9.74 | 12.53 | 10.04 | 9.24 | 5.37 | 6.85 |
| Total liabilities | 39.01 | 48.58 | 69.63 | 81.40 | 84.71 | 85.40 | 85.88 | 66.10 |
| Fixed assets | 17.90 | 20.76 | 29.39 | 36.12 | 57.22 | 54.15 | 55.50 | 48.08 |
| CWIP | 3.70 | 7.00 | 19.34 | 28.47 | 10.60 | 12.53 | 13.47 | -0.00 |
| Investments | 1.95 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 3.00 |
| Other assets | 15.46 | 20.82 | 20.90 | 16.81 | 16.89 | 18.72 | 16.91 | 15.02 |
| Total assets | 39.01 | 48.58 | 69.63 | 81.40 | 84.71 | 85.40 | 85.88 | 66.10 |
As reported by the company. Total assets equal total liabilities by construction.
Vanta Bioscience Ltd cash flow
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -1.04 | 2.34 | 6.97 | 5.28 | -0.63 | 2.68 | -2.41 | -5.22 |
| Cash from investing | -5.73 | -7.59 | -22.30 | -17.24 | -5.91 | -3.31 | -6.69 | -6.87 |
| Cash from financing | 9.94 | 2.17 | 17.78 | 9.53 | 6.41 | 0.69 | 9.16 | 12.08 |
| Net cash flow | 3.18 | -3.07 | 2.46 | -2.43 | -0.13 | 0.06 | 0.06 | -0.01 |
| Free cash flow | -3.52 | -5.01 | -15.23 | -11.90 | -6.54 | -0.63 | -9.10 | -12.09 |
| CFO / operating profit | -32% | 54% | 176% | 152% | 26% | 205% | 57% | -512% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Vanta Bioscience Ltd operating ratios
| Per year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | — | 8.35% | 5.21% | 3.77% | -5.82% | -4.16% | -11.58% | 1.19% |
| Debtor days | 47.14 | 36.90 | 74.71 | 43.88 | 122.71 | 117.91 | 465.56 | 513.41 |
| Inventory days | — | — | — | — | — | — | 2,400.15 | — |
| Days payable | — | — | — | — | — | — | 1,821.31 | — |
| Cash conversion cycle | 47.14 | 36.90 | 74.71 | 43.88 | 122.71 | 117.91 | 1,044.40 | 513.41 |
| Working capital days | 260.76 | 259.61 | 91.06 | -135.13 | -163.40 | -217.42 | -2,126.68 | 435.19 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Vanta Bioscience Ltd shareholding pattern
Promoters held 72.81% at Mar 2026, up from 69.36% at Sep 2024.
| % held | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | May 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 69.36% | 69.36% | 69.36% | 69.36% | 69.36% | 72.81% | 72.81% | 72.81% |
| Public | 30.65% | 30.64% | 30.64% | 30.64% | 30.64% | 27.18% | 27.19% | 27.18% |
| No. of shareholders | 394 | 388 | 418 | 424 | 408 | 408 | 419 | 426 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Vanta Bioscience Ltd corporate filings
- Vanta Bioscience Limited's AGM Voting Results Show Strong Shareholder Support for Financial Statements and Director Re-appointmentsAGM/EGMhigh impact
Cruxal's analysis: Vanta Bioscience Limited held its 10th AGM on September 30, 2026, with 440 shareholders…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
- Vanta Bioscience Ltd releases FY 2025-26 Annual ReportOtherslow impact
Cruxal's analysis: Vanta Bioscience has filed its Annual Report for the financial year 2025-26. The report…
Read the full analysis - Vanta Bioscience Limited schedules 10th Annual General Meeting for September 30, 2026Otherslow impact
Cruxal's analysis: Vanta Bioscience Limited has announced the scheduling of its 10th Annual General Meeting…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.